Tumour necrosis factor-α inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxiety

Journal of Psychosomatic Research

Volumn 79, Issue 3, 2015, Pages 175-184

  Abbott, Rebecca ^a   Whear, Rebecca ^a   Nikolaou, Vasilis ^a   Bethel, Alison ^a   Coon, Jo Thompson ^a   Stein, Ken ^a   Dickens, Chris ^a  

^a UNIVERSITY OF EXETER MEDICAL SCHOOL   (United Kingdom)

Author keywords

Chronic disease; Depression; Inflammation; Systematic review; TNF inhibitor

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; AUTACOID; BIOLOGICAL MARKER; TNF PROTEIN, HUMAN; TUMOR NECROSIS FACTOR;

AMED; ANKYLOSING SPONDYLITIS; ANXIETY DISORDER; BIBLIOGRAPHIC DATABASE; CENTRAL; CHRONIC DISEASE; CINAHL; COCHRANE LIBRARY; DATA EXTRACTION; DEPRESSION; DRUG EFFICACY; EMBASE; EVIDENCE BASED PRACTICE; HUMAN; MEDLINE; META ANALYSIS; MULTICENTER STUDY (TOPIC); PHYSICAL DISEASE; PSORIASIS; PSYCINFO; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; ANTAGONISTS AND INHIBITORS; ANXIETY; BLOOD; FEMALE; INFLAMMATION; PREVENTION AND CONTROL; PSYCHOLOGY;

ANXIETY; ARTHRITIS, RHEUMATOID; BIOMARKERS; CHRONIC DISEASE; DEPRESSION; FEMALE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84937973093     PISSN: 00223999     EISSN: 18791360     Source Type: Journal    
DOI: 10.1016/j.jpsychores.2015.04.008     Document Type: Review

References (59)

1. National Institute for Health and Clinical Excellence Depression in adults with a chronic physical health problem: treatment and management 2009, [London].
2. Katon WJ, Rutter C, Simon G, Lin EH, Ludman E, Ciechanowski P, et al. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 2005, 28:2668-2672.
3. Nicholson A, Kuper H, Hemingway H Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies. Eur Heart J 2006, 27:2763-2774.
4. Ellis C, Zhao Y, Egede LE Depression and increased risk of death in adults with stroke. J Psychosom Res 2010, 68:545-551.
5. van Melle JP, de Jonge P, Spijkerman TA, Tijssen JG, Ormel J, van Veldhuisen DJ, et al. Prognostic association of depression following myocardial infarction with mortality and cardiovascular events: a meta-analysis. Psychosom Med 2004, 66:814-822.
6. de Groot M, Anderson R, Freedland KE, Clouse RE, Lustman PJ Association of depression and diabetes complications: a meta-analysis. Psychosom Med 2001, 63:619-630.
7. Dickens CM, McGowan L, Percival C, Tomenson B, Cotter L, Heagerty A, et al. Contribution of depression and anxiety to impaired health-related quality of life following first myocardial infarction Br J Psychiatry 2006, 189:367-372.
8. Moussavi S, Chatterji S, Verdes E, Tandon A, Patel V, Ustun B Depression, chronic diseases, and decrements in health: results from the World Health Surveys. Lancet 2007, 370:851-858.
9. Keeley P, Creed F, Tomenson B, Todd C, Borglin G, Dickens C Psychosocial predictors of health-related quality of life and health service utilisation in people with chronic low back pain Pain 2008, 135:142-150.
10. Creed F, Morgan R, Fiddler M, Marshall S, Guthrie E, House A Depression and anxiety impair health-related quality of life and are associated with increased costs in general medical inpatients. Psychosomatics 2002, 43:302-309.
11. Gilmer TP, O'Connor PJ, Rush WA, Crain AL, Whitebird RR, Hanson AM, et al. Predictors of health care costs in adults with diabetes. Diabetes Care 2005, 28:59-64.
12. Dickens CM, Percival C, McGowan L, Douglas J, Tomenson B, Cotter L, et al. The risk factors for depression in first myocardial infarction patients. Psychol Med 2004, 34:1083-1092.
13. Dickens C, McGowan L, Percival C, Tomenson B, Cotter L, Heagerty A, et al. Negative illness perceptions are associated with new-onset depression following myocardial infarction Gen Hosp Psychiatry 2008, 30:414-420.
14. Dickens C, McGowan L, Clark-Carter D, Creed F Depression in rheumatoid arthritis: a systematic review of the literature with meta-analysis. Psychosom Med 2002, 64:52-60.
15. Prince MJ, Harwood RH, Thomas A, Mann AH A prospective population-based cohort study of the effects of disablement and social milieu on the onset and maintenance of late-life depression The Gospel Oak Project VII. Psychol Med 1998, 28:337-350.
16. Turvey CL, Schultz SK, Beglinger L, Klein DM A longitudinal community-based study of chronic illness, cognitive and physical function, and depression Am J Geriatr Psychiatry 2009, 17:632-641.
17. Harrison J, Maguire P Predictors of psychiatric morbidity in cancer patients. Br J Psychiatry 1994, 165:593-598.
18. Miller AH, Maletic V, Raison CL Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression Biol Psychiatry 2009, 65:732-741.
19. Valkanova V, Ebmeier KP, Allan CL CRP, IL-6 and depression: a systematic review and meta-analysis of longitudinal studies. J Affect Disord 2013, 150:736-744.
20. Howren MB, Lamkin DM, Suls J Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med 2009, 71:171-186.
21. Himmerich H, Fulda S, Linseisen J, Seiler H, Wolfram G, Himmerich S, et al. Depression, comorbidities and the TNF-alpha system. Eur Psychiatry 2008, 23:421-429.
22. Schmidt FM, Lichtblau N, Minkwitz J, Chittka T, Thormann J, Kirkby KC, et al. Cytokine levels in depressed and non-depressed subjects, and masking effects of obesity. J Psychiatr Res 2014, 55:29-34.
23. Gimeno D, Kivimaki M, Brunner EJ, Elovainio M, De Vogli R, Steptoe A, et al. Associations of C-reactive protein and interleukin-6 with cognitive symptoms of depression: 12-year follow-up of the Whitehall II study. Psychol Med 2009, 39:413-423.
24. Stewart JC, Rand KL, Muldoon MF, Kamarck TW A prospective evaluation of the directionality of the depression-inflammation relationship Brain Behav Immun 2009, 23:936-944.
25. Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry 2001, 58:445-452.
26. Wright CE, Strike PC, Brydon L, Steptoe A Acute inflammation and negative mood: mediation by cytokine activation Brain Behav Immun 2005, 19:345-350.
27. Beratis S, Katrivanou A, Georgiou S, Monastirli A, Pasmatzi E, Gourzis P, et al. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment. J Psychosom Res 2005, 58:15-18.
28. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 2001, 344:961-966.
29. Su KP, Lai HC, Yang HT, Su WP, Peng CY, Chang JP, et al. Omega-3 fatty acids in the prevention of interferon-alpha-induced depression: results from a randomized, controlled trial. Biol Psychiatry 2014, 76:559-566.
30. Liu H, Luiten PG, Eisel UL, Dejongste MJ, Schoemaker RG Depression after myocardial infarction: TNF-alpha-induced alterations of the blood-brain barrier and its putative therapeutic implications. Neurosci Biobehav Rev 2013, 37:561-572.
31. Krugel U, Fischer J, Radicke S, Sack U, Himmerich H Antidepressant effects of TNF-alpha blockade in an animal model of depression J Psychiatr Res 2013, 47:611-616.
32. Camara ML, Corrigan F, Jaehne EJ, Jawahar MC, Anscomb H, Baune BT Effects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge. Neuropsychopharmacology 2015, 40:502-512.
33. Lichtenstein G.R., Bala M., Han C., et al. Infliximab improves quality of life in patients with Crohn's disease. Inflamm Bowel Dis 2002, 8(4):237-243.
34. Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: the COMET trial. Ann Rheum Dis 2010, 69:222-225. [Erratum appears in Ann Rheum Dis. 2011 Aug;70(8):1519].
35. Arisoy O, Bes C, Cifci C, Sercan M, Soy M The effect of TNF-alpha blockers on psychometric measures in ankylosing spondylitis patients: a preliminary observation Rheumatol Int 2013, 33:1855-1864.
36. Ertenli I, Ozer S, Kiraz S, Apras SB, Akdogan A, Karadag O, et al. Infliximab, a TNF-alpha antagonist treatment in patients with ankylosing spondylitis: the impact on depression, anxiety and quality of life level. Rheumatol Int 2012, 32:323-330.
37. Vogelzangs N, Beekman AT, de Jonge P, Penninx BW Anxiety disorders and inflammation in a large adult cohort. Transl psychiatry 2013, 3:e249.
38. Centre for Reviews and Dissemination Systematic reviews: CRDs guidance for undertaking reviews in healthcare 2009, Centre for Reviews and Dissemination, University fo York, York.
39. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Br Med J 2009, 339:b2535.
40. Higgins JPT, Altman DG, Group obotCSM, Group.atCBM Assessing risk of bias in included studies. Cochrane handbook for systematic reviews of interventions: the cochrane collaboration 2008, J.P.T. Higgins, S. Green (Eds.).
41. van der Heijde D, Braun J, Dougados M, Sieper J, Pedersen R, Szumski A, et al. Sensitivity and discriminatory ability of the ankylosing spondylitis disease activity score in patients treated with etanercept or sulphasalazine in the ASCEND trial. Rheumatology (Oxford) 2012, 51:1894-1905.
42. Tyring S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006, 367:29-35.
43. Borenstein M, Hedges L, Higgins J, HR R Introduction to meta-analysis 2009, John Wilet & Sons, Chichester, UK.
44. Cummings P Meta-analysis based on standardized effects is unreliable. Arch Pediatr Adolesc Med 2004, 158:595-597.
45. Higgins JP, Thompson SG, Deeks JJ, Altman DG Measuring inconsistency in meta-analyses. Br Med J 2003, 327:557-560.
46. Cohen J Statistical power analysis for the behavioural sciences (2nd ed) 1988, Lawrence Erlbaum Associates, New Jersey.
47. Packham JC, Jordan KP, Haywood KL, Garratt AM, Healey EL Evaluation of Ankylosing Spondylitis Quality of Life questionnaire: responsiveness of a new patient-reported outcome measure. Rheumatology (Oxford) 2012, 51:707-714.
48. Bae SC, Gun SC, Mok CC, Khandker R, Nab HW, Koenig AS, et al. Improved health outcomes with etanercept versus usual DMARD therapy in an Asian population with established rheumatoid arthritis. BMC Musculoskelet Disord 2013, 14:13.
49. Machado DA, Guzman RM, Xavier RM, Simon JA, Mele L, Pedersen R, et al. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region J Clin Rheumatol 2014, 20:25-33.
50. Menter A, Augustin M, Signorovitch J, Yu AP, Wu EQ, Gupta SR, et al. The effect of adalimumab on reducing depression symptoms in patients with moderate to severe psoriasis: a randomized clinical trial. J Am Acad Dermatol 2010, 62:812-818.
51. Gordon KB, Langley RG, Leonardi C, Toth D, Menter MA, Kang S, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006, 55:598-606.
52. Braun J, van der Horst-Bruinsma IE, Huang F, Burgos-Vargas R, Vlahos B, Koenig AS, et al. Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 2011, 63:1543-1551.
53. Kim HY, Hsu PN, Barba M, Sulaiman W, Robertson D, Vlahos B, et al. Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial. Int J Rheum Dis 2012, 15:188-196.
54. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008, 372:375-382.
55. Dauden E, Griffiths CE, Ortonne JP, Kragballe K, Molta CT, Robertson D, et al. Improvements in patient-reported outcomes in moderate-to-severe psoriasis patients receiving continuous or paused etanercept treatment over 54weeks: the CRYSTEL study. J. Eur Acad Dermatol Venereol 2009, 23:1374-1382.
56. Gniadecki R, Robertson D, Molta CT, Freundlich B, Pedersen R, Li W, et al. Self-reported health outcomes in patients with psoriasis and psoriatic arthritis randomized to two etanercept regimens. J. Eur Acad Dermatol Venereol 2012, 26:1436-1443.
57. Loftus EV, Feagan BG, Colombel JF, Rubin DT, Wu EQ, Yu AP, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: patient-reported outcomes of the CHARM trial. [Erratum appears in Am J Gastroenterol. 2009 Jul;104(7):1894]. Am J Gastroenterol 2008, 103:3132-3141.
58. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, et al. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70:31-41.
59. Maas DW, Westendorp RG, Willems JM, de Craen AJ, van der Mast RC TNF-antagonist infliximab in the treatment of depression in older adults: results of a prematurely ended, randomized, placebo-controlled trial. J Clin Psychopharmacol 2010, 30:343-345.